Toutes les études
RecrutementPHASE1, PHASE2INTERVENTIONNEL

Étude de l'IDE196 chez les patients atteints de tumeurs solides portant des mutations GNAQ/11 ou des fusions PRKC

This research study is investigating a new medication called IDE196 for people with certain advanced solid cancers, including a type of eye cancer called uveal melanoma, skin cancer, or bowel cancer. These cancers must have particular genetic faults, known as GNAQ/11 mutations or PRKC fusions. The main goals are to find out if IDE196 is safe and how well it works. Researchers are testing IDE196 on its own and in combination with two other approved cancer drugs, binimetinib and crizotinib. The study has different stages: an early stage (Phase 1) to find the right dose, and a later stage (Phase 2) to see how effective that dose is. Some parts of the study looking at IDE196 alone or with binimetinib have already finished taking new patients.

En un coup d'œil

Statut
Recrutement
Phase
PHASE1, PHASE2
Sponsor
IDEAYA Biosciences
Objectif d'inscription
336
Démarrer
28 juin 2019
Achèvement estimé
15 Jun 2027

De quoi parle cette étude ?

This research study is designed to help us learn more about a new medicine called IDE196. It's for people who have advanced solid cancers, which means the cancer has spread from where it started. Specifically, it's for cancers that have certain genetic changes or 'faults' – imagine a tiny spelling mistake in the cancer's instruction manual – called GNAQ or GNA11 mutations, or PRKC fusions. These faults can be found in different types of cancer, including melanoma (a type of skin cancer, and specifically a rare kind that affects the eye called uveal melanoma) and bowel cancer, as well as other solid tumours.

The main idea behind this study is to see if IDE196 can safely and effectively treat these cancers. Researchers are testing IDE196 in a few ways: they're giving it on its own, and they're also trying it in combination with two other existing cancer drugs, binimetinib and crizotinib. The study is split into stages. Earlier stages focused on finding the safest and most effective dose of IDE196, both by itself and in combination with the other drugs. Later stages focused on seeing how well these doses work against the cancer.

It's important to know that some parts of this study have already finished taking new patients. For example, the parts looking at IDE196 on its own and IDE196 combined with binimetinib are no longer enrolling. This kind of research helps doctors understand new treatments better, so they can find new ways to help people living with cancer.

Points clés

  • This study investigates a new drug, IDE196, for advanced cancers with specific genetic changes.
  • It's exploring IDE196 alone and in combination with other existing cancer drugs.
  • The study aims to check the safety and effectiveness of IDE196.
  • It targets cancers like uveal melanoma, cutaneous melanoma, and colorectal cancer.
  • Some parts of the study are no longer accepting new patients.

Qui peut être éligible ?

To join this study, you need to be at least 18 years old. You must have a diagnosis of certain advanced solid cancers, such as metastatic uveal melanoma (a type of eye cancer that has spread), cutaneous melanoma (skin cancer), or bowel cancer, and these cancers need to have specific genetic changes (GNAQ/11 mutations or PRKC fusions). Your cancer might be new or it might have come back after previous treatments.

There are also some general health checks. For example, your organs (like your liver and kidneys) need to be working well, and you should be generally well enough to take part. For women who could become pregnant and men, you would need to use effective birth control during the study.

Some things might mean you can't join. For instance, if you've already had a specific type of treatment called a PKC inhibitor, or if you have certain infections like HIV or active Hepatitis B or C. Also, if your cancer has spread to your brain and is causing symptoms, you usually wouldn't be able to join. Your doctor will carefully review all your medical information to see if this study is right for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous au moins 18 ans ?
  2. Do you have advanced uveal melanoma, cutaneous melanoma, colorectal cancer, or another solid tumour?
  3. Does your cancer have GNAQ/11 mutations or PRKC fusions?
  4. Are you generally well enough to take part and do your organs work properly?
  5. Have you discussed birth control if you are of childbearing potential?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you would receive the new drug IDE196, either on its own or in combination with binimetinib or crizotinib. The study involves regular visits to the hospital for checks, which would include blood tests, scans (like CT scans) to see how the cancer is responding, and general health assessments. You'd also be asked questions about how you're feeling and any side effects you might be experiencing. Some people might need to have a new biopsy (a small sample of tissue taken) if the doctors need more information about their cancer. The exact number of visits and the total length of time you'd be in the study would depend on which part of the study you join and how your body responds to the treatment. This will all be explained in detail by the study team.

Risques et avantages potentiels

Taking part in a clinical trial may offer potential benefits, such as access to a new treatment (IDE196) that isn't widely available yet, which might help your cancer. However, there are also potential risks, as IDE196 is an experimental drug, and its full side effects are still being understood. You might experience side effects common to other cancer treatments, or entirely new ones. The study team will closely monitor you for any side effects. It's very important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (15)

  • UCLA Medical Center
    Code postal vérifié
    Los Angeles, États-Unis· Recrutement
  • San Francisco Oncology Associates
    Code postal vérifié
    San Francisco, États-Unis· Actif, mais pas en recrutement
  • SCRI - Denver
    Code postal vérifié
    Denver, United States· Recrutement
  • Université de l'Iowa
    Code postal vérifié
    Iowa City, États-Unis· Actif, mais pas en recrutement
  • Cancer Hematology Centers Western Michigan
    Code postal vérifié
    Grand Rapids, United States· Actif, mais pas en recrutement
  • Columbia University Medical Center - Herbert Irving Pavilion
    Code postal vérifié
    New York, États-Unis· Actif, mais pas en recrutement
  • Centre Médical de l'Université Duke
    Code postal vérifié
    Durham, États-Unis· Recrutement
  • University of Cincinnati Cancer Center
    Code postal vérifié
    Cincinnati, United States· Recrutement
  • The Cleveland Clinic Foundation
    Code postal vérifié
    Cleveland, United States· Actif, mais pas en recrutement
  • Sidney Kimmel Cancer Center at Thomas Jefferson University
    Code postal vérifié
    Philadelphie, États-Unis· Recrutement
  • The Sarah Cannon Research Institute/Tennessee Oncology
    Code postal vérifié
    Nashville, United States· Recrutement
  • The University of Texas MD Anderson Cancer Center
    Code postal vérifié
    Houston, États-Unis· Recrutement

Questions fréquentes

What is IDE196?

IDE196 is a new experimental drug being tested to treat certain advanced cancers with specific genetic changes.

Pour quel type de cancers cette étude est-elle destinée ?

This study is for advanced solid cancers like a type of eye cancer (uveal melanoma), skin cancer (cutaneous melanoma), or bowel cancer, that have specific genetic changes called GNAQ/11 mutations or PRKC fusions.

Is IDE196 given alone or with other drugs?

IDE196 is being tested both on its own and in combination with two approved cancer drugs, binimetinib and crizotinib.

Are new patients still being accepted into this study?

Some parts of the study, specifically looking at IDE196 alone and IDE196 with binimetinib, have finished taking new patients. Your doctor can tell you if any other parts are still open.

What are GNAQ/11 mutations or PRKC fusions?

These are specific genetic changes or 'faults' found in the cancer cells that the new drug, IDE196, is designed to target.

Comment en savoir plus

IDEAYA Clinical Trials

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.